NewLink Genetics Corporation, a biotech firm developing a Phase 3 drug for surgically-resected pancreatic cancer patients, announced terms for its IPO on Wednesday. The Ames, IA-based company plans to raise $61 million by offering 5.5 million shares at a price range of $10.00 to $12.00. At the mid-point of the proposed range, NewLink Genetics Corporation will command a market value of $223 million. NewLink Genetics Corporation, which was founded in 1999 and booked $2 million in sales for the 12 months ended June 30, 2011, plans to list on the NASDAQ under the symbol NLNK. Stifel Nicolaus Weisel and Canaccord Genuity are the lead underwriters on the deal.
